Last reviewed · How we verify
Reyataz (ATAZANAVIR)
Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV.
Reyataz (atazanavir) is a protease inhibitor, a type of antiretroviral medication originally developed by Bristol Myers Squibb. It targets the UDP-glucuronosyltransferase 1-1 enzyme and is used to treat human immunodeficiency virus (HIV) infection. Reyataz was FDA-approved in 2003 and is now available as a generic medication. As an off-patent medication, it is no longer protected by active patents, allowing multiple generic manufacturers to produce it. Key safety considerations include monitoring for liver enzyme elevations and potential interactions with other medications.
At a glance
| Generic name | ATAZANAVIR |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Protease Inhibitor |
| Target | UDP-glucuronosyltransferase 1-1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2003 |
Mechanism of action
EVOTAZ is fixed-dose tablet consisting of the HIV-1 antiretroviral drug, atazanavir and the CYP3A inhibitor, cobicistat [see Microbiology (12.4)].
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Drug interaction
- Foetal exposure during pregnancy
- Depression
- Virologic failure
- Abortion spontaneous
- Hyperbilirubinaemia
- Nephrolithiasis
- Exposure during pregnancy
- Lipodystrophy acquired
- Psychiatric decompensation
- Premature baby
- Renal colic
Drug interactions
- CYP3A4 Substrates
- alfentanil
- atorvastatin
- bosentan
- cimetidine
- clarithromycin
- conivaptan
- delavirdine
- didanosine
- efavirenz
- erlotinib
- erythromycin
Key clinical trials
- Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV (PHASE3)
- Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s) (PHASE3)
- A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine (PHASE3)
- BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2,PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reyataz CI brief — competitive landscape report
- Reyataz updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI